HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

Abstract
Neuroblastoma is a common childhood tumor comprising cases with rapid disease progression as well as spontaneous regression. Although numerous prognostic factors have been identified, risk evaluation in individual patients remains difficult. To define a reliable prognostic predictor and gene signatures characteristic of biological subgroups, we performed mRNA expression profiling of 68 neuroblastomas of all stages. Expression data were analysed using support vector machines (SVM-rbf), prediction analysis of microarrays (PAM), k-nearest neighbors (k-NN) algorithms and multiple decision trees. SVM-rbf performed best of all methods, and predicted recurrence of neuroblastoma with an accuracy of 85% (sensitivity 77%, specificity 94%). PAM identified a classifier of 39 genes reliably predicting outcome with an accuracy of 80%. In comparison, conventional risk stratification based on stage, age and MYCN-status only reached a predictive accuracy of 64%. Kaplan-Meier analysis using the PAM classifier indicated a 5-year survival of 20 versus 78% for patients with unfavorably versus favorably predicted neuroblastomas, respectively (P = 0.0001). Significance analysis of microarrays (SAM) identified additional genes differentially expressed among subgroups. MYCN-amplification and high expression of NTRK1/TrkA demonstrated a strong association with specific gene expression patterns. Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and defining biological properties of neuroblastoma.
AuthorsAlexander Schramm, Johannes H Schulte, Ludger Klein-Hitpass, Werner Havers, Hauke Sieverts, Bernd Berwanger, Holger Christiansen, Patrick Warnat, Benedikt Brors, Jürgen Eils, Roland Eils, Angelika Eggert
JournalOncogene (Oncogene) Vol. 24 Issue 53 Pg. 7902-12 (Nov 24 2005) ISSN: 0950-9232 [Print] England
PMID16103881 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Nuclear Proteins
  • Oncogene Proteins
  • RNA, Messenger
  • Receptor, trkA
Topics
  • Algorithms
  • Cohort Studies
  • Decision Trees
  • Gene Amplification
  • Gene Expression Profiling
  • Humans
  • Infant
  • Infant, Newborn
  • N-Myc Proto-Oncogene Protein
  • Neoplasm Staging
  • Neuroblastoma (genetics, pathology)
  • Nuclear Proteins (genetics)
  • Oligonucleotide Array Sequence Analysis
  • Oncogene Proteins (genetics)
  • Prognosis
  • RNA, Messenger (analysis)
  • Receptor, trkA (genetics)
  • Risk Assessment
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: